EGFR and lung carcinoma: Recent studies have shown that lung cancer with increased YES1 was more responsive to Dasatinib (44), and increased expression of YES1 was reported to be one of the acquired resistant mechanisms to EGFR inhibitors in lung cancer with EGFR mutations (45).